Adams Jennifer Mckie Sells Shares of Eton Pharmaceuticals, Inc. $ETON

Key Points

  • Adams Jennifer Mckie sold 50,000 shares of Eton Pharmaceuticals, Inc. ($ETON).
  • $ETON last traded around $32.76.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Adams Jennifer Mckie, insider at Eton Pharmaceuticals, Inc. ($ETON), sold 50,000 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Eton Pharmaceuticals, Inc. Stock Down 45.2%

Shares of Eton Pharmaceuticals, Inc. ($ETON) traded around $32.76 on Thursday, down 45.2% for the day.

Last price$32.76
Market cap$1.73B
P/E ratio154.97
Forward P/E23.43
Beta0.87
52-week low$14.27
52-week high$66.37
50-day MA$45.63
200-day MA$27.41
Current ratio1.52
Quick ratio1.15
Debt-to-equity0.63

Eton Pharmaceuticals, Inc. Earnings

EPS (ttm)$0.39
Revenue (ttm)$105.59M
Revenue growth98.60%
Net margin12.02%
Return on equity35.97%
Next earningsNov 12, 2026

Analysts Set New Price Targets

Average target$71
High target$76
Low target$68
Analysts covering4

About Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

ExchangeNasdaqGM
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersDeer Park, IL
CEOMr. Sean E. Brynjelsen
Employees44

Get Eton Pharmaceuticals, Inc. alerts

New 13F filings, insider trades, and analyst moves on $ETON, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.